Fluoguide AS
STO:FLUO
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
33.9
75.6
|
Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Fluoguide AS
Accounts Payable
Fluoguide AS
Accounts Payable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Accounts Payable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
F
|
Fluoguide AS
STO:FLUO
|
Accounts Payable
kr4.1m
|
CAGR 3-Years
15%
|
CAGR 5-Years
214%
|
CAGR 10-Years
N/A
|
|
Genmab A/S
CSE:GMAB
|
Accounts Payable
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Zealand Pharma A/S
CSE:ZEAL
|
Accounts Payable
kr229.7m
|
CAGR 3-Years
61%
|
CAGR 5-Years
50%
|
CAGR 10-Years
38%
|
||
Ascendis Pharma A/S
NASDAQ:ASND
|
Accounts Payable
€75.3m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
25%
|
CAGR 10-Years
38%
|
||
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Accounts Payable
kr1.1B
|
CAGR 3-Years
56%
|
CAGR 5-Years
59%
|
CAGR 10-Years
29%
|
|
Bioporto A/S
CSE:BIOPOR
|
Accounts Payable
kr5.5m
|
CAGR 3-Years
16%
|
CAGR 5-Years
18%
|
CAGR 10-Years
13%
|
Fluoguide AS
Glance View
FluoGuide A/S engages in the development of surgical solutions to reduce suffering for the patient and increase the likelihood of cure; as well as reducing costs for the health care system. The firm develops surgical solutions, which expected to reduce Cancer pain for the patient and increases the possibility of recovering as well as reducing costs for the health care system. The first product is the compound FG001, which lights up the cancer and its invasive growth into the surrounding tissue.
See Also
What is Fluoguide AS's Accounts Payable?
Accounts Payable
4.1m
DKK
Based on the financial report for Dec 31, 2023, Fluoguide AS's Accounts Payable amounts to 4.1m DKK.
What is Fluoguide AS's Accounts Payable growth rate?
Accounts Payable CAGR 5Y
214%
Over the last year, the Accounts Payable growth was 155%. The average annual Accounts Payable growth rates for Fluoguide AS have been 15% over the past three years , 214% over the past five years .